ProCE Banner Activity

TITAN: Phase III Trial of Apalutamide vs Placebo in Patients With Metastatic Castration-Sensitive Prostate Cancer Receiving ADT

Slideset Download
Conference Coverage
Apalutamide plus ADT significantly improved OS and rPFS vs placebo plus ADT in patients with metastatic castration-sensitive prostate cancer.

Released: June 07, 2019

Expiration: June 05, 2020

Share

Provided by

Provided by the USF Health
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Astellas Seattle Genetics

Bayer Healthcare Pharma

Blueprint Medicines

Celgene

Novartis Pharmaceuticals Corporation

Puma Biotechnology, Inc.

Taiho Oncology Inc

Tesaro